Published in Lancet on August 18, 2012
Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma (DREAM) | NCT01000506
Exploring Asthma Exacerbations in Mepolizumab Treated Patients | NCT03324230
Wessex Asthma Cohort of Difficult Asthma (WATCH) | NCT03996590
Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. Am J Respir Crit Care Med (2013) 4.95
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med (2017) 4.55
IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med (2014) 3.32
Eosinophils: changing perspectives in health and disease. Nat Rev Immunol (2012) 2.69
Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med (2014) 2.56
A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J (2015) 1.82
Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol (2015) 1.70
Severe asthma: definition, diagnosis and treatment. Dtsch Arztebl Int (2014) 1.61
Airway smooth muscle in the pathophysiology and treatment of asthma. J Appl Physiol (1985) (2013) 1.56
OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy (2014) 1.54
Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov (2013) 1.47
Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol (2014) 1.43
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol (2013) 1.42
An epigenome-wide association study of total serum immunoglobulin E concentration. Nature (2015) 1.37
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med (2014) 1.37
The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat Rev Immunol (2014) 1.25
Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.13
Asthma: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc (2014) 1.12
The potential of biologics for the treatment of asthma. Nat Rev Drug Discov (2012) 1.11
The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med (2014) 1.11
Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov (2015) 1.05
Prostaglandin D₂ pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol (2013) 1.04
Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol (2015) 1.00
Refractory asthma: mechanisms, targets, and therapy. Allergy (2014) 0.99
Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med (2013) 0.97
A qPCR-based metric of Th2 airway inflammation in asthma. Clin Transl Allergy (2013) 0.97
Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm (2015) 0.97
Eosinophils in mucosal immune responses. Mucosal Immunol (2015) 0.97
Increased nuclear suppressor of cytokine signaling 1 in asthmatic bronchial epithelium suppresses rhinovirus induction of innate interferons. J Allergy Clin Immunol (2015) 0.96
Efficacy of anti-interleukin-5 therapy with mepolizumab in patients with asthma: a meta-analysis of randomized placebo-controlled trials. PLoS One (2013) 0.95
Nonadherence in difficult asthma - facts, myths, and a time to act. Patient Prefer Adherence (2013) 0.94
Development of New Therapies for Severe Asthma. Allergy Asthma Immunol Res (2017) 0.94
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? NPJ Prim Care Respir Med (2014) 0.92
Update on anticytokine treatment for asthma. Biomed Res Int (2013) 0.92
Current concepts of severe asthma. J Clin Invest (2016) 0.91
Activation states of blood eosinophils in asthma. Clin Exp Allergy (2014) 0.90
Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract (2015) 0.90
Integrin activation States and eosinophil recruitment in asthma. Front Pharmacol (2013) 0.89
Type-2 innate lymphoid cells in human allergic disease. Curr Opin Allergy Clin Immunol (2014) 0.89
A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res (2013) 0.88
Multi-scale computational models of the airways to unravel the pathophysiological mechanisms in asthma and chronic obstructive pulmonary disease (AirPROM). Interface Focus (2013) 0.88
Biologics in asthma--the next step toward personalized treatment. J Allergy Clin Immunol Pract (2015) 0.88
Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of calcitriol. J Allergy Clin Immunol (2015) 0.88
Toll-like receptor 7 governs interferon and inflammatory responses to rhinovirus and is suppressed by IL-5-induced lung eosinophilia. Thorax (2015) 0.86
Severe asthma: anti-IgE or anti-IL-5? Eur Clin Respir J (2016) 0.86
Early-life viral infections and the development of asthma: a target for asthma prevention? Curr Opin Allergy Clin Immunol (2014) 0.86
Relationship between blood and bronchial submucosal eosinophilia and reticular basement membrane thickening in chronic obstructive pulmonary disease. Respirology (2015) 0.85
Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol (2014) 0.85
Eosinophils in the spotlight: Finding the link between obesity and asthma. Nat Med (2013) 0.85
Statistical cluster analysis of the British Thoracic Society Severe refractory Asthma Registry: clinical outcomes and phenotype stability. PLoS One (2014) 0.84
Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol (2016) 0.84
Serum periostin in obstructive airways disease. Eur Respir J (2016) 0.83
The consequences of not having eosinophils. Allergy (2013) 0.83
Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors. CPT Pharmacometrics Syst Pharmacol (2013) 0.83
In-stent restenosis exacerbated by drug-induced severe eosinophilia after second-generation drug-eluting stent implantation. Am J Case Rep (2014) 0.83
Tailored therapy for severe asthma. Multidiscip Respir Med (2015) 0.83
Hypoxia potentiates allergen induction of HIF-1α, chemokines, airway inflammation, TGF-β1, and airway remodeling in a mouse model. Clin Immunol (2013) 0.82
Eosinophilic bioactivities in severe asthma. World Allergy Organ J (2016) 0.82
Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis (2016) 0.81
Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy (2016) 0.81
Cytokine profiles in nasal fluid of patients with seasonal or persistent allergic rhinitis. Allergy Asthma Clin Immunol (2015) 0.81
Semaphorin 7A is expressed on airway eosinophils and upregulated by IL-5 family cytokines. Clin Immunol (2013) 0.81
Eosinophil apoptosis and clearance in asthma. J Cell Death (2013) 0.81
Inflammatory and Co-Morbid Features of Patients with Severe Asthma and Frequent Exacerbations. Am J Respir Crit Care Med (2016) 0.80
Severe asthma in children. J Allergy Clin Immunol Pract (2014) 0.80
Role of prostaglandin D2 /CRTH2 pathway on asthma exacerbation induced by Aspergillus fumigatus. Immunology (2014) 0.80
Bystander immunotherapy as a strategy to control allergen-driven airway inflammation. Mucosal Immunol (2014) 0.79
Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res (2015) 0.79
Relationships among aeroallergen sensitization, peripheral blood eosinophils, and periostin in pediatric asthma development. J Allergy Clin Immunol (2016) 0.79
Anti-IL5 therapy for asthma and beyond. World Allergy Organ J (2014) 0.79
Asthma Was Talking, But We Weren't Listening. Missed or Ignored Signals That Have Slowed Treatment Progress. Ann Am Thorac Soc (2016) 0.79
Thiol redox chemistry: role of protein cysteine oxidation and altered redox homeostasis in allergic inflammation and asthma. J Cell Biochem (2015) 0.79
Biomarkers and severe asthma: a critical appraisal. Clin Mol Allergy (2015) 0.79
Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res (2016) 0.79
Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy (2016) 0.78
COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med (2014) 0.78
Update on reslizumab for eosinophilic asthma. Expert Opin Biol Ther (2015) 0.78
Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther (2015) 0.78
Novel Therapies for Eosinophilic Disorders. Immunol Allergy Clin North Am (2015) 0.78
Novel targeted therapies for eosinophil-associated diseases and allergy. Annu Rev Pharmacol Toxicol (2014) 0.78
Defining the roles of IL-33, thymic stromal lymphopoietin, and IL-25 in human asthma. Am J Respir Crit Care Med (2014) 0.78
The relationship between eosinophilia and airway remodelling in mild asthma. Clin Exp Allergy (2013) 0.78
Interaction between allergy and innate immunity: model for eosinophil regulation of epithelial cell interferon expression. Ann Allergy Asthma Immunol (2013) 0.77
Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17. Br J Pharmacol (2016) 0.77
From bedside to bench to clinic trials: identifying new treatments for severe asthma. Dis Model Mech (2013) 0.77
Role of monoclonal antibodies in the treatment of asthma. Can Respir J (2013) 0.77
Retrospective cohort analysis of healthcare claims in the United States characterising asthma exacerbations in paediatric patients. World Allergy Organ J (2016) 0.77
Eosinophilia in mast cell disease. Immunol Allergy Clin North Am (2014) 0.77
The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. J Asthma Allergy (2015) 0.77
United airway disease: current perspectives. J Asthma Allergy (2016) 0.77
Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res (2015) 0.76
Mepolizumab for severe eosinophilic asthma. Expert Rev Respir Med (2013) 0.76
Novel strategies for the treatment of asthma. Allergo J Int (2016) 0.76
Personalized Medicine in Allergy. Allergy Asthma Immunol Res (2017) 0.76
Emergence of Biomolecular Pathways to Define Novel Asthma Phenotypes. Type-2 Immunity and Beyond. Am J Respir Cell Mol Biol (2016) 0.76
Targeting IL-5 in severe asthma: a DREAM come true? Lancet (2012) 0.76
Novel diagnostic approaches and biological therapeutics for intrinsic asthma. Int J Gen Med (2014) 0.76
Severe Asthma: The Evolution of Patient-directed Management. Clin Pulm Med (2014) 0.76
Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery. J Clin Med (2016) 0.76
B cells in transplantation. J Heart Lung Transplant (2016) 0.75
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med (2004) 10.31
An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med (2009) 9.38
The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 8.43
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20
Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med (2009) 7.17
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol (2007) 6.33
Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29
Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med (2010) 6.19
Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med (2004) 5.04
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med (2014) 4.95
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med (2003) 4.46
Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet (2011) 3.68
Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med (2002) 3.68
Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med (2014) 3.50
Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol (2010) 3.12
Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol (1985) (2007) 2.83
Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax (2010) 2.79
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
We should prohibit warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2015) 2.63
Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma. Am J Hum Genet (2001) 2.61
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med (2009) 2.56
Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol (2010) 2.51
Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med (2015) 2.44
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol (2010) 2.27
Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J Natl Cancer Inst (2003) 2.26
Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol (2004) 2.22
Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol (2010) 2.20
Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet (2002) 2.15
Reduction of airway smooth muscle mass by bronchial thermoplasty in patients with severe asthma. Am J Respir Crit Care Med (2014) 2.15
Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest (2003) 2.04
Fine mapping and positional candidate studies identify HLA-G as an asthma susceptibility gene on chromosome 6p21. Am J Hum Genet (2004) 2.03
Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest (2008) 1.89
Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation (2002) 1.85
An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med (2012) 1.85
Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol (2013) 1.80
Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med (2011) 1.76
Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. Am J Respir Crit Care Med (2005) 1.72
Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways. Am J Respir Crit Care Med (2014) 1.69
Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations. J Allergy Clin Immunol (2003) 1.69
Variable-length poly-C tract polymorphisms of the beta2-adrenergic receptor 3'-UTR alter expression and agonist regulation. Am J Physiol Lung Cell Mol Physiol (2007) 1.66
Obesity and asthma: an association modified by age of asthma onset. J Allergy Clin Immunol (2011) 1.64
Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med (2008) 1.64
Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med (2006) 1.59
MicroRNAs and respiratory diseases. Eur Respir J (2012) 1.59
Importance of hedgehog interacting protein and other lung function genes in asthma. J Allergy Clin Immunol (2011) 1.58
IL4R alpha mutations are associated with asthma exacerbations and mast cell/IgE expression. Am J Respir Crit Care Med (2006) 1.57
Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med (2012) 1.57
New horizons in early stage COPD--improving knowledge, detection and treatment. Respir Med (2011) 1.56
Further replication studies of the EVE Consortium meta-analysis identifies 2 asthma risk loci in European Americans. J Allergy Clin Immunol (2012) 1.54
Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer (2002) 1.53
Genome-wide search for atopy susceptibility genes in Dutch families with asthma. J Allergy Clin Immunol (2002) 1.50
Major recessive gene(s) with considerable residual polygenic effect regulating adult height: confirmation of genomewide scan results for chromosomes 6, 9, and 12. Am J Hum Genet (2002) 1.47
Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol (2010) 1.47
Predicting future risk of asthma exacerbations using individual conditional probabilities. J Allergy Clin Immunol (2011) 1.46
Supplementing defect in club cell secretory protein attenuates airway inflammation in COPD. Chest (2015) 1.45
Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med (2008) 1.45
Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol (2005) 1.42
Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. J Allergy Clin Immunol (2008) 1.42
Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol (2010) 1.41
Associations between fluctuations in lung function and asthma control in two populations with differing asthma severity. Thorax (2011) 1.39
Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol (2009) 1.38
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax (2010) 1.36
24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J (2012) 1.36
Identification of PCDH1 as a novel susceptibility gene for bronchial hyperresponsiveness. Am J Respir Crit Care Med (2009) 1.35
ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med (2008) 1.34
Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir Res (2009) 1.34
Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score. Dtsch Arztebl Int (2017) 1.34
A genome-wide search for quantitative trait loci contributing to variation in seasonal pollen reactivity. J Allergy Clin Immunol (2006) 1.32
Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res (2010) 1.31
Predictors of uncontrolled asthma in adult and pediatric patients: analysis of the Asthma Control Characteristics and Prevalence Survey Studies (ACCESS). J Asthma (2010) 1.30
Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther (2006) 1.30
Specific IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol (2012) 1.28
Evidence for gene-environment interactions in a linkage study of asthma and smoking exposure. J Allergy Clin Immunol (2003) 1.27
Association of IL1RL1, IL18R1, and IL18RAP gene cluster polymorphisms with asthma and atopy. J Allergy Clin Immunol (2008) 1.27
Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Respir Res (2009) 1.25
Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med (2003) 1.23
Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol (2005) 1.23
Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol (2005) 1.23
Solitary cystic mediastinal lymphangioma. Eur Respir Rev (2013) 1.23
Do symptoms predict COPD in smokers? Chest (2010) 1.22
The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol (2009) 1.21
A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med (2008) 1.21
Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? Thorax (2013) 1.20
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J (2013) 1.20
Genome screen for asthma and bronchial hyperresponsiveness: interactions with passive smoke exposure. J Allergy Clin Immunol (2005) 1.19
Interleukin 13 and interleukin 4 receptor-α polymorphisms in rhinitis and asthma. Int Arch Allergy Immunol (2010) 1.17
Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res (2002) 1.17